Table 1 Baseline characteristics of MRS development and validation cohorts.
From: A methylation risk score for chronic kidney disease: a HyperGEN study
N (%)/Mean (SD) | Development | Validation | |||||
|---|---|---|---|---|---|---|---|
HyperGEN* (N = 608) | GOLDN (N = 993) | JHS* (N = 1709) | MESA-AA* (N = 182) | WHI-AS311 (N = 145) | WHI-BAA23 (N = 2049) | WHI-EMPC (N = 1172) | |
Age | 48.4 (11.1) | 49.4 (15.9) | 56.2 (12.3) | 60.9 (9.6) | 66.3 (7.1) | 64.5 (7.1) | 62.5 (6.9) |
Sex, Male | 204 (33.6) | 474 (47.7) | 637 (37.3) | 77 (42.3) | 0 (0.0%) | ||
Race, Black | 608 (100) | 0 (0) | 1,709 (100) | 181 (100) | 51 (35.2) | 665 (32.5) | 416 (35.5) |
Current Smoker | 191 (31.4) | 81 (8.2) | 243 (14.2) | 34 (18.7) | 25 (17.2) | 208 (10.2) | 112 (9.6) |
BMI | 32.4 (8.2) | 28.3 (5.5) | 32.0 (7.4) | 30.6 (5.6) | 29.8 (7.3) | 29.8 (6.1) | 29.8 (5.9) |
Diabetes | 122 (20.1) | 77 (7.8) | 394 (23.1) | 61 (33.5) | 14 (9.7) | 210 (10.2) | 82 (7.0) |
Hypertension | 460 (75.7) | 256 (25.8) | 1,002 (58.6) | 105 (57.7) | 31 (21.4) | 451 (22.0) | 181 (15.4) |
CKD | 37 (6.1) | 6 (0.6) | 142 (8.3) | 15 (8.2) | 0 (0) | 19 (0.9) | 7 (0.6) |
Stage G2 | 173 (28.5) | 127 (12.8) | 449 (26.3) | 56 (30.8) | 5 (3.4) | 119 (5.8) | 60 (5.1) |
eGFR | 102.4 (29.5) | 123.0 (34.8) | 92.1 (25.4) | 90.9 (25.9) | 134.4 (31.1) | 136.5 (33.6) | 136.7 (30.0) |
